Assessment of the use of the speculum for intravitreal injections of anti-VEGF.
Pablo Carnota
PC
Méndez
Carlos Méndez
CM
Vázquez
Jaime Otero
JO
Villar
José Antonio Saavedra
JA
Pazos
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D003229:Conjunctival Diseases / Q000209:etiology; D005130:Eye Hemorrhage / Q000209:etiology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections / Q000009:adverse effects*; D008297:Male; D009885:Ophthalmology / Q000295:instrumentation*; D017060:Patient Satisfaction; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab